Published: 12 July 2022
Author(s): Shu Li, Fen Li, Ni Mao, Jia Wang, Xi Xie
Section: Letter to the Editor

We appreciate the opportunity to reply to the Letter to the Editor by Dimosiari and colleagues [1], commenting on our work [2]. We concur with them that the cardiovascular disease (CVD) risk of Janus kinase (JAK) inhibitors in patients with ankylosing spondylitis (AS) deserves attention.


Stay informed on our latest news!


This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.